InTrack Investment Management Inc Makes New $522,000 Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

InTrack Investment Management Inc purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 7,658 shares of the company’s stock, valued at approximately $522,000.

Several other large investors have also made changes to their positions in the company. ARK Investment Management LLC boosted its stake in shares of CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after acquiring an additional 1,372,986 shares in the last quarter. Capital International Investors raised its position in shares of CRISPR Therapeutics by 0.8% in the fourth quarter. Capital International Investors now owns 6,134,450 shares of the company’s stock valued at $384,017,000 after purchasing an additional 48,938 shares during the period. Vanguard Group Inc. raised its position in shares of CRISPR Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company’s stock valued at $99,575,000 after purchasing an additional 51,926 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock worth $40,879,000 after buying an additional 15,085 shares during the period. Finally, Norges Bank bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $38,661,000. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the transaction, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

CRSP has been the subject of a number of research analyst reports. Wells Fargo & Company cut their target price on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Mizuho increased their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Robert W. Baird lifted their price target on CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Piper Sandler reissued an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Finally, Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $75.71.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded down $0.84 during trading hours on Tuesday, hitting $53.12. The company had a trading volume of 1,058,868 shares, compared to its average volume of 1,643,101. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10. The firm’s fifty day moving average is $56.62 and its 200 day moving average is $64.40. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of -19.53 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $25.53 million. CRISPR Therapeutics’s revenue for the quarter was down 99.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.67) EPS. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.51 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.